Clinical Trials/General Drug Development Strategy & Practice

024: The Clinical Evaluation of QTc Interval Prolongation for the Dual Endothelin Receptor Antagonist Aprocitentan in a Thorough QT/QTc Study

025: Safety, Tolerability & Pharmacokinetics of Single-dose INCB000928 & Food Effect on INCB000928 in Healthy Adult Participants

026: Pharmacokinetic, Food Effect, Safety & Tolerability Evaluations of Gepotidacin in Healthy Japanese Participants

027: Engraftment of Investigational Microbiome Therapeutic SER-109 is Durable Through 24 Weeks in a Randomized Trial (ECOSPOR III) for the Treatment of Recurrent Clostridioides Difficile Infection

029: Multiple-ascending Dose Study With ACT-1014-6470, an Oral Complement Factor 5a Receptor 1 Antagonist, Demonstrated Target Engagement by Ex Vivo Matrix Metalloproteinase 9 Stimulation

030: Evaluation of Subject Populations Enrolled in Bioequivalence Studies for Generic Drug Development

031: Comparison of the Pharmacokinetics, Safety & Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects

032: Assessment of Riluzole Therapeutic Effects on Spinal Cord Injury

033: Pharmacokinetic Bioequivalence Evaluation of a Fixed-dose Combination of Empagliflozin L-Proline/Metformin in Healthy Korean Subjects

034: Novel Oral Complement Factor 5a Receptor 1 Antagonist ACT-1014-6470 for the Treatment of Rare Inflammatory Diseases: Single-ascending Dose Study Including Food Effect Assessment

034: Novel Oral Complement Factor 5a Receptor 1 Antagonist ACT-1014-6470 for the Treatment of Rare Inflammatory Diseases: Single-ascending Dose Study Including Food Effect Assessment